Companion Diagnostics Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2020 – 2025

1
Companion Diagnostics Market

• Size 2018, By Products Services (Assays, Kits
  Reagents, Software Services), By Technology
  (Polymerase Chain Reaction (PCR), Next-Generation
  Sequencing (NGS), In Situ Hybridization (ISH),
  Immunohistochemistry (ICH), Others), By
  Application (Cancer, Cardiovascular Diseases,
  Infectious Diseases, Neurological Diseases,
  Others), By Region and Forecast 2019 to 2025

Single Use License US 4400
Request Sample
2
Companion Diagnostics Market Size and Share 2025

• The global companion diagnostics market is
  projected to reach an approximate value of USD
  9.2 billion by 2025, growing at a CAGR of 14.2.
  Increasing demand for personalized medicine, rise
  in incidence of cancer, increasing investments in
  RD for the development of biomarkers and
  companion diagnostics tests are factors driving
  the global companion diagnostics market.
• Adroit Market Research report on global companion
  diagnostics market gives a holistic view of the
  market from 2015 to 2025, which includes factors
  such as market drivers, restraints, opportunities
  and challenges. The market has been studied for
  historic years from 2015 to 2017, with the base
  year of estimation as 2018 and forecast from 2019
  to 2025. The report covers the current status and
  future traits of the market at global as well as
  country level. In addition, the study also
  assesses the market based on Porter's five forces
  analysis and positions the key players based on
  their product portfolio, geographic footprint,
  strategic initiatives and overall revenue.
  Prominent players operating in the global
  companion diagnostics market have been studied in
  detail.
• Companion diagnostics (CDx) are tests that are
  developed alongside drugs in the drug development
  process in order to determine whether or not the
  patient is a candidate for the particular
  therapy. Such tests are increasingly found in the
  oncology field where the use of very expensive
  therapies is at stake. There is rapid adoption of
  companion diagnostic tests in clinical
  laboratories owing to increase in collaborations
  between pharmaceutical and diagnostic companies
  for the development of companion diagnostic
  tests, which is likely to escalate the growth of
  the market. For instance, EGFR for lung cancer,
  KRAS for colon cancer, BCR-ABL for chronic
  myelogenous leukemia and BRAF for melanoma are
  some of the major companion diagnostic tests
  available in the market for tumor detection.

3
Companion Diagnostics Market Size and Share 2025

• The global companion diagnostics market has been
  segmented based on products services,
  application, technology, and region. Based on
  products services, the global companion
  diagnostics market is categorized into assays,
  kits reagents, and software services. On the
  basis of application, the global companion
  diagnostics market is segmented into cancer,
  neurological diseases, infectious diseases,
  cardiovascular diseases, and others. Cancer held
  majority of the market share in 2018.
  Technology-wise, the global companion diagnostics
  market is segregated into polymerase chain
  reaction (PCR), next-generation sequencing (NGS),
  immunohistochemistry (ICH), in situ hybridization
  (ISH), and others.
• Geographically, North America dominated the
  global companion diagnostics market in 2018. Wide
  availability of companion diagnostics tests and
  services, favourable reimbursement scenario,
  increase in volume of clinical trials and drug
  approval rates, presence of well-established
  healthcare facilities, and high prevalence of
  cancer in the region are key factors likely to
  drive the growth of the market in the next few
  years.
• Major players operating in the global companion
  diagnostics market include Qiagen N.V., F.
  Hoffmann-La Roche, Agilent Technologies Inc.,
  Pfizer, Abbott Laboratories, AstraZeneca, Thermo
  Fisher Scientific, bioMérieux SA, Myriad
  Genetics, and Illumina, Inc. among others.

4
Companion Diagnostics Market Size and Share 2025

• Key Segments of the Global Companion Diagnostics
  Market
• Products Services Overview, 2015-2025 (USD
  Million)
• Assays, Kits Reagents
• Software Services
• Application Overview, 2015-2025 (USD Million)
• Cancer
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Melanoma
• Leukemia
• Others
• Infectious Diseases
• Cardiovascular Diseases
• Neurological Diseases
• Others

5
About Us

• Adroit Market Research is an India-based business
  analytics and consulting company. Our target
  audience is a wide range of corporations,
  manufacturing companies, product/technology
  development institutions and industry
  associations that require understanding of a
  markets size, key trends, participants and
  future outlook of an industry. We intend to
  become our clients knowledge partner and provide
  them with valuable market insights to help create
  opportunities that increase their revenues. We
  follow a code Explore, Learn and Transform. At
  our core, we are curious people who love to
  identify and understand industry patterns, create
  an insightful study around our findings and churn
  out money-making roadmaps. Our analysts have
  tracked high growth markets in chemicals
  materials, healthcare pharmaceuticals,
  semiconductor electronics, energy power, food
  retail, consumer goods, technology, and
  machinery equipment sectors across the world to
  identify new opportunities, potential customers,
  prepare go-to-market (GTM) strategies, identify
  segments for revenue growth for companies, and
  many more.

• US Headquarters3131 McKinney Ave Ste 600
  Dallas, TX 75204 ,U.S.A 

• Phone [phone]
• Email sales_at_adroitmarketresearch.com